T2 Biosystems, Inc. (NASDAQ:TTOO) diagnostic products and services provider, is reporting third quarter earnings results on Wednesday 4th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.08 per share.
For the full year, analysts predict revenues of $ 18.98 million, while looking forward to loss of $ 0.41 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 18.00 million ~ $ 20.00 million
Click Here For More Historical Outlooks Of T2 Biosystems, Inc.
Previous Quarter Performance
T2 Biosystems, Inc. communicated loss for the second quarter of $ 0.09 per share, from the revenue of $ 2.55 million. The quarterly revenues elevated 27.50 percent compared with the same quarter last year. Street analysts expected T2 Biosystems, Inc. to report loss of $ 0.15 per share on revenue of $ 2.37 million for the second quarter. The bottom line results beat street analysts by $ 0.06 or 40.00 percent, at the same time, top line results outshined analysts by $ 0.18 million or 7.59 percent.
Stock Performance
Shares of T2 Biosystems, Inc. traded up $ 0.03 or 2.27 percent on Tuesday, reaching $ 1.35 with volume of 2.39 million shares. T2 Biosystems, Inc. has traded high as $ 1.38 and has cracked $ 1.31 on the downward trend
According to the previous trading day, closing price of $ 1.35, representing a 450.00 % increase from the 52 week low of $ 0.24 and a 54.48 % decrease over the 52 week high of $ 2.90.
The company has a market capital of $ 199.73 million and is part of the Healthcare sector and Diagnostics & Research industry.
Conference Call
T2 Biosystems, Inc. will be hosting a conference call at 4:30 PM eastern time on 4th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.t2biosystems.com
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company also offers T2Dx, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood.
